Zynerba Pharmaceuticals, Inc. Quarterly Nonoperating Income (Expense) in USD from Q3 2015 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Zynerba Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2015 to Q2 2023.
  • Zynerba Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2023 was $360K.
  • Zynerba Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2023 was $1.2M.
  • Zynerba Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $216K.
  • Zynerba Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was -$539K, a 174% decline from 2020.
  • Zynerba Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2020 was $726K, a 47.3% decline from 2019.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $1.2M $360K +$1.04M Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $160K $357K -$56K -13.5% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $216K $670K +$649K +3035% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-28
Q3 2022 -$433K -$183K +$188K +50.7% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q2 2022 -$621K -$684K -$573K -513% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$48.5K $413K +$490K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$539K $21.4K -$550K -96.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 $11.8K -$372K -$555K -303% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $567K -$112K -$1.62M -107% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $2.19M -$76.8K +$1.46M +95% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $726K $572K -$129K -18.4% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-10
Q3 2020 $855K $183K +$203K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $652K $1.51M +$1.13M +301% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$482K -$1.54M -$1.86M -582% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $1.38M $701K +$445K +174% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-10
Q3 2019 $931K -$20.2K -$198K -111% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-10
Q2 2019 $1.13M $376K +$413K Apr 1, 2019 Jun 30, 2019 10-K 2021-03-10
Q1 2019 $716K $319K +$230K +256% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-10
Q4 2018 $487K $256K +$170K +198% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 $317K $178K -$60.1K -25.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-10
Q2 2018 $377K -$37.4K -$79.6K -189% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-10
Q1 2018 $456K $89.8K -$354K -79.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-10
Q4 2017 $811K $85.9K +$298K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-11
Q3 2017 $513K $238K +$222K +1347% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-11
Q2 2017 $291K $42.2K +$44.3K Apr 1, 2017 Jun 30, 2017 10-K 2019-03-11
Q1 2017 $247K $444K +$455K Jan 1, 2017 Mar 31, 2017 10-K 2019-03-11
Q4 2016 -$208K -$212K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-12
Q3 2016 $16.5K +$14.9K +948% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-12
Q2 2016 -$2.13K Apr 1, 2016 Jun 30, 2016 10-K 2018-03-12
Q1 2016 -$10.8K Jan 1, 2016 Mar 31, 2016 10-K 2018-03-12
Q3 2015 $1.57K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.